Ivermectin's Role in Cancer Research

Hi, everyone. It's a really exciting time right now

with, uh, ivermectin in

cancer research. There are now six active clinical trials

investigating, uh, ivermectin in cancer. Last year, there were only two.

Uh, five of those clinical trials are in Florida, and one of them is in

California. The one in California is actually going to finish, uh, next

month. Uh, one of the Florida ones is gonna finish next year, and then

there's four new ones that are coming on board.

And this is really thanks to the efforts of Casey

DeSantis, uh, wife of the amazing, uh, governor of Florida, Ron

DeSantis. They've really spearheaded, uh, this exciting

cancer research. Uh, they've allocated at least sixty million

dollars.

I believe this year it's seventy million dollars.

Uh, it could go up to a hundred and forty million dollars.

And so by next year, we could see a dozen clinical trials,

uh, examining ivermectin in cancer. Uh, it's really, really exciting.

Uh, any of the AI, uh, assistants will tell you

that antiparasitics like ivermectin, mebendazole, fenbendazole,

niclosamide, and so on, these are the most,

uh, interesting, uh, drugs to repurpose for

cancer and drugs that have the mo- by far the most potential.

Now, that comes with a lot of pushback.

Uh, you see the constant daily attacks

that I'm exposed to.

Um, just the constant abuse, the pushback from the

cancer drug industry, which is terrified.

The, the cancer drug industry has two hundred

and ninety billion dollars of

annual revenue to protect. That's a lot of money.

Two hundred and ninety billion dollars every single year, and they hope that the

cancer drug industry will get up to five hundred billion dollars just in the

next few years.

So they're protecting their honeypot, and you've got

doctors attacking me who are absolutely terrified.

Um, the other day, I had a Stanford doctor who's a big-time

cancer

executive just attack me ruthlessly out of nowhere.

I've never met the guy. I don't know who the guy is.

Um, they're scared. They're scared, and they should be.

Uh, this is absolutely exciting. It, it's, it's breaking

the mainstream oncology paradigm and

the monopoly that they have on, on

cancer research and cancer drugs.

All we see from mainstream oncology are, you know,

three, four hundred thousand dollar cancer drugs

that barely work

or that provide you maybe an extra couple of months of survival benefit at best

and have hor-horrific side effects.

All of these cancer drugs that cost hundreds of thousands of dollars

have

terrible side effects. And ivermectin and mebendazole have

virtually no side effects. They break through all of that nonsense.

And yeah, it's a ninety-nine point nine percent

revenue loss

for them, so they aren't gonna do any research to

put themselves out of business.

So very exciting times. I'm gonna keep you updated. Stay tuned.